Full-Time
Manager Capital Investment Strategy
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
Compensation Overview
€78.3k - €135.7k/yr
Umkirch, Germany + 1 more
More locations: Norderstedt, Germany
Remote
Field-based role with approximately 50–70% travel required.
 Business & Strategy (1) |
|---|
Get referred to Johnson & Johnson
See people who can refer or advise you
- Several years of experience, ideally 3–5 or more, selling or managing products involving capital-intensive medical devices such as robotics, power tools, or operating-room equipment.
- Demonstrated experience in multi-stakeholder sales, developing clinical-economic business cases, and negotiating capital-equipment transactions.
- Good knowledge of clinical workflows, operating-room procedures, and hospital structures, including an understanding of diagnosis-related-group and budget logic.
- An analytical mindset, commercial acumen, and experience with pricing and return-on-investment models.
- An entrepreneurial mindset, high ownership, and results orientation.
- A strong and convincing presence with decision-makers and internal stakeholders.
- A structured, data-driven approach with clear prioritization and a hands-on mentality.
- Strong communication and presentation skills.
- A completed degree in engineering, business administration, or a comparable field.
- Very good German and good English language skills.
- Willingness to travel approximately 50–70%.
- Own the national capital-equipment strategy for robotics and power tools, including segmentation, target customers, objectives, and the execution roadmap.
- Develop and prioritize target accounts using market mapping, data insights, and economic potential.
- Build robust business cases and investment plans covering volume assumptions, return on investment, and risk analysis to support decisions and resource allocation.
- Manage the capital-sales cycle, including multi-stakeholder selling, clinical-economic argumentation, procurement alignment, and offer and contract management.
- Define pricing strategies and value ladders for systems, consumables, service, and software, including discount guardrails and profitability targets.
- Lead launch preparation for robotic systems through readiness checks, milestones, go-to-market planning, and operational launch coordination.
- Manage tender and project business, including compliant offers, internal resource coordination, and project support through implementation.
- Manage stakeholders at management and C-level, as well as surgeons, operating-room teams, and procurement, to promote adoption and strategic partnerships.
- Enable the field sales organization by creating playbooks, conducting joint customer visits, handling objections, and sharing best practices.
- Coordinate closely with the Velys Joints team to harmonize the robotics strategy and transfer proven approaches.
- An MBA is preferred.
- Experience with account management, alliance formation, customer experience management, process improvements, revenue management, sales projections, solutions selling, sustainable procurement, vendor selection, medical technology, personalized services, technical credibility, commercial awareness, customer centricity, execution focus, goal orientation, interpersonal influence, market knowledge, and retail promotions.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
- TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
- The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.
What critics are saying
- Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
- The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
- A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.
What makes Johnson & Johnson unique
- J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
- TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
- TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -2%The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.
Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.
Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.
Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.
Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.